The positive and negative cardiovascular effects of cannabis

References

• DeFilippis EM, Bajaj NS, Singh A, et al. Marijuana use in patients with cardiovascular disease: JACC review topic of the week. J Am Coll Cardiol. 2020;75:320–332.
   PubMed Web of Science ®Google Scholar
• Wilkinson ST, Yarnell S, Radhakrishnan R, et al. Marijuana legalization: impact on physicians and public health. Annu Rev Med. 2016;67:453–466.
   PubMed Web of Science ®Google Scholar
• Bhatnagar A, Whitsel LP, Ribisl KM, et al. American heart association advocacy coordinating committee CoC, stroke nursing CoCC, council on quality of C and outcomes R. Electronic cigarettes: a policy statement from the American heart association. Circulation. 2014;130:1418–1436.
   PubMed Web of Science ®Google Scholar
• Xu DH, Cullen BD, Tang M, et al. The effectiveness of topical cannabidiol oil in symptomatic relief of peripheral neuropathy of the lower extremities. Curr Pharm Biotechnol. 2019;21(5):390-402.
   Web of Science ®Google Scholar
• Pacher P, Steffens S, Hasko G, et al. Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. Nat Rev Cardiol. 2018;15:151–166.
   PubMed Web of Science ®Google Scholar
• Subramaniam VN, Menezes AR, DeSchutter A, et al. The cardiovascular effects of marijuana: are the potential adverse effects worth the high? Mo Med. 2019;116:146–153.
   PubMedGoogle Scholar
• Lee G, Grovey B, Furnish T, et al. Medical cannabis for neuropathic pain. Curr Pain Headache Rep. 2018;22:8.
   PubMed Web of Science ®Google Scholar
• Sharkey KA, Darmani NA, Parker LA. Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system. Eur J Pharmacol. 2014;722:134–146.
   PubMed Web of Science ®Google Scholar
• Kaufman TM, Fazio S, Shapiro MD. Brief commentary: marijuana and cardiovascular disease-what should we tell patients? Ann Intern Med. 2019;170:119–120.
   PubMed Web of Science ®Google Scholar
• Atakan Z. Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol. 2012;2:241–254.
   PubMedGoogle Scholar
• Terry-McElrath YM, O’Malley PM, Johnston LD. Alcohol and marijuana use patterns associated with unsafe driving among U.S. high school seniors: high use frequency, concurrent use, and simultaneous use. J Stud Alcohol Drugs. 2014;75:378–389.
   PubMed Web of Science ®Google Scholar
• D’Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29:1558–1572.
   PubMed Web of Science ®Google Scholar
• Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4:1770–1804.
   PubMed Web of Science ®Google Scholar
• Spindle TR, Bonn-Miller MO, Vandrey R. Changing landscape of cannabis: novel products, formulations, and methods of administration. Curr Opin Psychol. 2019;30:98–102.
   PubMed Web of Science ®Google Scholar
• Lu HC, Mackie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016;79:516–525.
   PubMed Web of Science ®Google Scholar
• Schneider-Smith E, Salottolo K, Swartwood C, et al. Matched pilot study examining cannabis-based dronabinol for acute pain following traumatic injury. Trauma Surg Acute Care Open. 2020;5:e000391.
   PubMedGoogle Scholar
• Tsang CC, Giudice MG. Nabilone for the management of pain. Pharmacotherapy. 2016;36:273–286.
   PubMed Web of Science ®Google Scholar
• Abuhasira R, Shbiro L, Landschaft Y. Medical use of cannabis and cannabinoids containing products - Regulations in Europe and North America. Eur J Intern Med. 2018;49:2–6.
   PubMed Web of Science ®Google Scholar
• Canada S National Cannabis Survey 2nd quarter, 2019. Component of Statistics Canada catalogue no 11-001-X. 2019.
   Google Scholar
• Lafaye G, Karila L, Belcha L, et al. Cannabis, cannabinoids, and health. Dialogues Clin Neurosci. 2017;19:309–316.
   PubMed Web of Science ®Google Scholar
• ElSohly MA, Mehmedic Z, Foster S, et al. Changes in cannabis potency over the last 2 decades (1995-2014): analysis of current data in the United States. Biol Psychiatry. 2016;79:613–619.
   PubMed Web of Science ®Google Scholar
• Giroud C, de Cesare M, Berthet A, et al. E-cigarettes: a review of new trends in cannabis use. Int J Environ Res Public Health. 2015;12:9988–10008.
   PubMed Web of Science ®Google Scholar
• Hill GED, Izquierdo DA, Boettcher BT, et al. Chronic marijuana and synthetic cannabinoid-induced toxic myocarditis and end-stage cardiomyopathy: management with mechanical circulatory support as a bridge-to-transplantation. J Cardiothorac Vasc Anesth. 2019;33:2508–2512.
   PubMed Web of Science ®Google Scholar
• Stanley CP, Hind WH, O’Sullivan SE. Is the cardiovascular system a therapeutic target for cannabidiol? Br J Clin Pharmacol. 2013;75:313–322.
   PubMed Web of Science ®Google Scholar
• Pacher P, Kogan NM, Mechoulam R. Beyond THC and Endocannabinoids. Annu Rev Pharmacol Toxicol. 2020;60:637–659.
   PubMed Web of Science ®Google Scholar
• Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58:389–462.
   PubMed Web of Science ®Google Scholar
• Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci. 2018;19.
   Web of Science ®Google Scholar
• Mackie K. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol. 2008;20(Suppl 1):10–14.
   PubMedGoogle Scholar
• Borowska M, Czarnywojtek A, Sawicka-Gutaj N, et al. The effects of cannabinoids on the endocrine system. Endokrynol Pol. 2018;69:705–719.
   PubMedGoogle Scholar
• Sidibeh CO, Pereira MJ, Lau Borjesson J, et al. Role of cannabinoid receptor 1 in human adipose tissue for lipolysis regulation and insulin resistance. Endocrine. 2017;55:839–852.
   PubMed Web of Science ®Google Scholar
• Benowitz NL, Jones RT, Lerner CB. Depression of growth hormone and cortisol response to insulin-induced hypoglycemia after prolonged oral delta-9-tetrahydrocannabinol administration in man. J Clin Endocrinol Metab. 1976;42:938–941.
   PubMed Web of Science ®Google Scholar
• Friedman D, Devinsky O. Cannabinoids in the treatment of epilepsy. N Engl J Med. 2015;373:1048–1058.
   PubMed Web of Science ®Google Scholar
• Hughes CL Jr., Everett JW, Tyrey L. Delta 9-tetrahydrocannabinol suppression of prolactin secretion in the rat: lack of direct pituitary effect. Endocrinology. 1981;109:876–880.
   PubMed Web of Science ®Google Scholar
• Carvalho RK, Andersen ML, Mazaro-Costa R. The effects of cannabidiol on male reproductive system: A literature review. J Appl Toxicol. 2020;40:132–150.
   PubMed Web of Science ®Google Scholar
• Camilleri M. Cannabinoids and gastrointestinal motility: pharmacology, clinical effects, and potential therapeutics in humans. Neurogastroenterol Motil. 2018;30:e13370.
   PubMed Web of Science ®Google Scholar
• Perisetti A, Rimu AH, Khan SA, et al. Role of cannabis in inflammatory bowel diseases. Ann Gastroenterol. 2020;33:134–144.
   PubMed Web of Science ®Google Scholar
• Dibba P, Li AA, Cholankeril G, et al. Potential mechanisms influencing the inverse relationship between cannabis and nonalcoholic fatty liver disease: a commentary. Nutr Metab Insights. 2019;12:1178638819847480.
   Web of Science ®Google Scholar
• Vazquez-Bourgon J, Ortiz-garcia de la Foz V, Suarez-Pereira I, et al. Cannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first episode non-affective psychosis patients. Prog Neuropsychopharmacol Biol Psychiatry. 2019;95:109677.
   PubMed Web of Science ®Google Scholar
• Simons-Linares CR, Barkin JA, Jang S, et al. The impact of cannabis consumption on mortality, morbidity, and cost in acute pancreatitis patients in the united states: a 10-year analysis of the national inpatient sample. Pancreas. 2019;48:850–855.
   PubMedGoogle Scholar
• Romero-Sandoval EA, Fincham JE, Kolano AL, et al. Cannabis for Chronic Pain: challenges and Considerations. Pharmacotherapy. 2018;38:651–662.
   PubMed Web of Science ®Google Scholar
• Liu CS, Chau SA, Ruthirakuhan M, et al. Cannabinoids for the treatment of agitation and aggression in alzheimer’s disease. CNS Drugs. 2015;29:615–623.
   PubMed Web of Science ®Google Scholar
• Cassano T, Villani R, Pace L, et al. From cannabis sativa to cannabidiol: promising therapeutic candidate for the treatment of neurodegenerative diseases. Front Pharmacol. 2020;11:124.
   PubMed Web of Science ®Google Scholar
• Antonazzo M, Botta M, Bengoetxea H, et al. Therapeutic potential of cannabinoids as neuroprotective agents for damaged cells conducing to movement disorders. Int Rev Neurobiol. 2019;146:229–257.
   PubMed Web of Science ®Google Scholar
• Rajesh M, Batkai S, Kechrid M, et al. Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. Diabetes. 2012;61:716–727.
   PubMed Web of Science ®Google Scholar
• El-Remessy AB, Rajesh M, Mukhopadhyay P, et al. Cannabinoid 1 receptor activation contributes to vascular inflammation and cell death in a mouse model of diabetic retinopathy and a human retinal cell line. Diabetologia. 2011;54:1567–1578.
   PubMed Web of Science ®Google Scholar
• Rajesh M, Mukhopadhyay P, Hasko G, et al. Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells. Br J Pharmacol. 2010;160:688–700.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay P, Rajesh M, Batkai S, et al. CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. Cardiovasc Res. 2010;85:773–784.
   PubMed Web of Science ®Google Scholar
• Pacher P, Batkai S, Kunos G. Cardiovascular pharmacology of cannabinoids. Handb Exp Pharmacol. 2005;599–625.
   PubMedGoogle Scholar
• Han KH, Lim S, Ryu J, et al. CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. Cardiovasc Res. 2009;84:378–386.
   PubMed Web of Science ®Google Scholar
• Sugamura K, Sugiyama S, Nozaki T, et al. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation. 2009;119:28–36.
   PubMed Web of Science ®Google Scholar
• Molica F, Burger F, Thomas A, et al. Endogenous cannabinoid receptor CB1 activation promotes vascular smooth-muscle cell proliferation and neointima formation. J Lipid Res. 2013;54:1360–1368.
   PubMed Web of Science ®Google Scholar
• Rajesh M, Mukhopadhyay P, Hasko G, et al. Cannabinoid CB1 receptor inhibition decreases vascular smooth muscle migration and proliferation. Biochem Biophys Res Commun. 2008;377:1248–1252.
   PubMed Web of Science ®Google Scholar
• Pacher P, Mechoulam R. Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res. 2011;50:193–211.
   PubMed Web of Science ®Google Scholar
• Sterin-Borda L, Del Zar CF, Borda E. Differential CB1 and CB2 cannabinoid receptor-inotropic response of rat isolated atria: endogenous signal transduction pathways. Biochem Pharmacol. 2005;69:1705–1713.
   PubMed Web of Science ®Google Scholar
• Cota D. CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab Res Rev. 2007;23:507–517.
   PubMed Web of Science ®Google Scholar
• Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005;115:1298–1305.
   PubMed Web of Science ®Google Scholar
• Cota D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003;112:423–431.
   PubMed Web of Science ®Google Scholar
• Cavuoto P, McAinch AJ, Hatzinikolas G, et al. The expression of receptors for endocannabinoids in human and rodent skeletal muscle. Biochem Biophys Res Commun. 2007;364:105–110.
   PubMed Web of Science ®Google Scholar
• Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. 2005;310:329–332.
   PubMed Web of Science ®Google Scholar
• Ofek O, Karsak M, Leclerc N, et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A. 2006;103:696–701.
   PubMed Web of Science ®Google Scholar
• Galiegue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995;232:54–61.
   PubMedGoogle Scholar
• Matyas C, Erdelyi K, Trojnar E, et al. Interplay of liver-heart inflammatory axis and cannabinoid 2 receptor signaling in an experimental model of hepatic cardiomyopathy. Hepatology. 2020;71:1391–1407.
   PubMed Web of Science ®Google Scholar
• Jouanjus E, Raymond V, Lapeyre-Mestre M, et al. What is the current knowledge about the cardiovascular risk for users of cannabis-based products? A systematic review. Curr Atheroscler Rep. 2017;19:26.
   PubMed Web of Science ®Google Scholar
• Page RL 2nd, Allen LA, Kloner RA, et al. Medical marijuana, recreational cannabis, and cardiovascular health: a scientific statement from the American heart association. Circulation. 2020;CIR0000000000000883.
   Google Scholar
• Calapai F, Cardia L, Sorbara EE, et al. Cannabinoids, blood-brain barrier, and brain disposition. Pharmaceutics. 2020;12(3):265.
   Google Scholar
• Singh A, Saluja S, Kumar A, et al. Cardiovascular complications of marijuana and related substances: a review. Cardiol Ther. 2018;7:45–59.
   PubMed Web of Science ®Google Scholar
• Su Z, Preusser L, Diaz G, et al. Negative inotropic effect of a CB2 agonist A-955840 in isolated rabbit ventricular myocytes is independent of CB1 and CB2 receptors. Curr Drug Saf. 2011;6:277–284.
   PubMedGoogle Scholar
• Bonz A, Laser M, Kullmer S, et al. Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharmacol. 2003;41:657–664.
   PubMed Web of Science ®Google Scholar
• Grigoriadis CE, Cork DP, Dembitsky W, et al. Recurrent cardiogenic shock associated with cannabis use: report of a case and review of the literature. J Emerg Med. 2019;56:319–322.
   Google Scholar
• Kariyanna PT, Jayarangaiah A, Singh N, et al. Marijuana induced myocarditis: a new entity of toxic myocarditis. Am J Med Case Rep. 2018;6:169–172.
   Google Scholar
• Mittleman MA, Lewis RA, Maclure M, et al. Triggering myocardial infarction by marijuana. Circulation. 2001;103:2805–2809.
   PubMed Web of Science ®Google Scholar
• Tatli E, Yilmaztepe M, Altun G, et al. Cannabis-induced coronary artery thrombosis and acute anterior myocardial infarction in a young man. Int J Cardiol. 2007;120:420–422.
   PubMed Web of Science ®Google Scholar
• Caldicott DG, Holmes J, Roberts-Thomson KC, et al. Keep off the grass: marijuana use and acute cardiovascular events. Eur J Emerg Med. 2005;12:236–244.
   PubMed Web of Science ®Google Scholar
• Frost L, Mostofsky E, Rosenbloom JI, et al. Marijuana use and long-term mortality among survivors of acute myocardial infarction. Am Heart J. 2013;165:170–175.
   PubMed Web of Science ®Google Scholar
• Cathel AM, Reyes BA, Wang Q, et al. Cannabinoid modulation of alpha2 adrenergic receptor function in rodent medial prefrontal cortex. Eur J Neurosci. 2014;40:3202–3214.
   PubMed Web of Science ®Google Scholar
• Alshaarawy O, Elbaz HA. Cannabis use and blood pressure levels: United States national health and nutrition examination survey, 2005-2012. J Hypertens. 2016;34:1507–1512.
   PubMed Web of Science ®Google Scholar
• Dumont GJ, Kramers C, Sweep FC, et al. Cannabis coadministration potentiates the effects of “ecstasy” on heart rate and temperature in humans. Clin Pharmacol Ther. 2009;86:160–166.
   PubMed Web of Science ®Google Scholar
• Hodcroft CJ, Rossiter MC, Buch AN. Cannabis-associated myocardial infarction in a young man with normal coronary arteries. J Emerg Med. 2014;47:277–281.
   PubMed Web of Science ®Google Scholar
• Dahdouh Z, Roule V, Lognone T, et al. Cannabis and coronary thrombosis: what is the role of platelets? Platelets. 2012;23:243–245.
   PubMed Web of Science ®Google Scholar
• Ducros A, Boukobza M, Porcher R, et al. The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients. Brain. 2007;130:3091–3101.
   PubMed Web of Science ®Google Scholar
• El Omri N, Eljaoudi R, Mekouar F, et al. Cannabis arteritis. Pan Afr Med J. 2017;26:53.
   PubMed Web of Science ®Google Scholar
• Gunawardena MD, Rajapakse S, Herath J, et al. Myocardial infarction following cannabis induced coronary vasospasm. BMJ Case Rep. 2014;2014:bcr2014207020.
   Google Scholar
• Baskaran J, Anantha Narayanan M, Vakhshoorzadeh J, et al. Marijuana-induced coronary vasospasm with persistent inter-coronary connection: a case report and review of literature. Cureus. 2019;11:e4799.
   Google Scholar
• Mendizabal VE, Adler-Graschinsky E. Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. Br J Pharmacol. 2007;151:427–440.
   PubMed Web of Science ®Google Scholar
• Wang X, Derakhshandeh R, Liu J, et al. One minute of marijuana secondhand smoke exposure substantially impairs vascular endothelial function. J Am Heart Assoc. 2016;5(8):e003858.
   Web of Science ®Google Scholar
• Singla S, Sachdeva R, Mehta JL. Cannabinoids and atherosclerotic coronary heart disease. Clin Cardiol. 2012;35:329–335.
   PubMed Web of Science ®Google Scholar
• Deusch E, Kress HG, Kraft B, et al. The procoagulatory effects of delta-9-tetrahydrocannabinol in human platelets. Anesth Analg. 2004;99:1127–1130. table of contents.
   PubMed Web of Science ®Google Scholar
• Sarafian TA, Magallanes JA, Shau H, et al. Oxidative stress produced by marijuana smoke. An adverse effect enhanced by cannabinoids. Am J Respir Cell Mol Biol. 1999;20:1286–1293.
   PubMed Web of Science ®Google Scholar
• Hall W, Degenhardt L. Prevalence and correlates of cannabis use in developed and developing countries. Curr Opin Psychiatry. 2007;20:393–397.
   PubMed Web of Science ®Google Scholar
• Patton GC, Coffey C, Carlin JB, et al. Reverse gateways? Frequent cannabis use as a predictor of tobacco initiation and nicotine dependence. Addiction. 2005;100:1518–1525.
   PubMed Web of Science ®Google Scholar
• Gledhill-Hoyt J, Lee H, Strote J, et al. Increased use of marijuana and other illicit drugs at US colleges in the 1990s: results of three national surveys. Addiction. 2000;95:1655–1667.
   PubMed Web of Science ®Google Scholar
• Farokhnia M, McDiarmid GR, Newmeyer MN, et al. Effects of oral, smoked, and vaporized cannabis on endocrine pathways related to appetite and metabolism: a randomized, double-blind, placebo-controlled, human laboratory study. Transl Psychiatry. 2020;10:71.
   PubMed Web of Science ®Google Scholar
• Horvath B, Mukhopadhyay P, Hasko G, et al. The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. Am J Pathol. 2012;180:432–442.
   PubMed Web of Science ®Google Scholar
• Gruden G, Barutta F, Kunos G, et al. Role of the endocannabinoid system in diabetes and diabetic complications. Br J Pharmacol. 2016;173:1116–1127.
   PubMed Web of Science ®Google Scholar
• Johnson DW, Gunn JW Jr. Dangerous drugs: adulterants, diluents, and deception in street samples. J Forensic Sci. 1972;17:629–639.
   PubMedGoogle Scholar
• Seltenrich N. Into the weeds: regulating pesticides in cannabis. Environ Health Perspect. 2019;127:42001.
   PubMed Web of Science ®Google Scholar
• Punja ZK, Collyer D, Scott C, et al. Pathogens and molds affecting production and quality of cannabis sativa L. Front Plant Sci. 2019;10:1120.
   PubMed Web of Science ®Google Scholar
• Ge J, Yu H, Li J, et al. Assessment of aflatoxin B1 myocardial toxicity in rats: mitochondrial damage and cellular apoptosis in cardiomyocytes induced by aflatoxin B1. J Int Med Res. 2017;45:1015–1023.
   PubMed Web of Science ®Google Scholar
• Wu Q, Jezkova A, Yuan Z, et al. Biological degradation of aflatoxins. Drug Metab Rev. 2009;41:1–7.
   PubMed Web of Science ®Google Scholar
• Hall W, Hoch E, Lorenzetti V. Cannabis use and mental health: risks and benefits. Eur Arch Psychiatry Clin Neurosci. 2019;269:1–3.
   PubMed Web of Science ®Google Scholar
• Cohen BE, Edmondson D, Kronish IM. State of the art review: depression, stress, anxiety, and cardiovascular disease. Am J Hypertens. 2015;28:1295–1302.
   PubMed Web of Science ®Google Scholar
• Bautista LE, Vera-Cala LM, Colombo C, et al. Symptoms of depression and anxiety and adherence to antihypertensive medication. Am J Hypertens. 2012;25:505–511.
   PubMed Web of Science ®Google Scholar
• Janszky I, Ahnve S, Lundberg I, et al. Early-onset depression, anxiety, and risk of subsequent coronary heart disease: 37-year follow-up of 49,321 young Swedish men. J Am Coll Cardiol. 2010;56:31–37.
   PubMed Web of Science ®Google Scholar
• Durst R, Danenberg H, Gallily R, et al. Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. Am J Physiol Heart Circ Physiol. 2007;293:H3602–7.
   PubMed Web of Science ®Google Scholar
• Walsh SK, Hepburn CY, Kane KA, et al. Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion. Br J Pharmacol. 2010;160:1234–1242.
   PubMed Web of Science ®Google Scholar
• Resstel LB, Tavares RF, Lisboa SF, et al. 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol. 2009;156:181–188.
   PubMed Web of Science ®Google Scholar
• Jadoon KA, Tan GD, O’Sullivan SE. A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study. JCI Insight. 2017;2(12):e93760.
   Web of Science ®Google Scholar
• Lee WS, Erdelyi K, Matyas C, et al. T cell-mediated chronic autoimmune myocarditis: implications to autoimmune disorders and organ transplantation. Mol Med. 2016;22:136–146.
   PubMed Web of Science ®Google Scholar
• Hao E, Mukhopadhyay P, Cao Z, et al. Cannabidiol protects against doxorubicin-induced cardiomyopathy by modulating mitochondrial function and biogenesis. Mol Med. 2015;21:38–45.
   PubMed Web of Science ®Google Scholar
• Rajesh M, Mukhopadhyay P, Batkai S, et al. Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am J Physiol Heart Circ Physiol. 2007;293:H610–9.
   PubMed Web of Science ®Google Scholar
• Rajesh M, Mukhopadhyay P, Batkai S, et al. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol. 2010;56:2115–2125.
   PubMed Web of Science ®Google Scholar
• Hammell DC, Zhang LP, Ma F, et al. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. Eur J Pain. 2016;20:936–948.
   PubMed Web of Science ®Google Scholar
• Baron EP. Medicinal properties of cannabinoids, terpenes, and flavonoids in cannabis, and benefits in migraine, headache, and pain: an update on current evidence and cannabis science. Headache. 2018;58:1139–1186.
   PubMed Web of Science ®Google Scholar
• Vuckovic S, Srebro D, Vujovic KS, et al. Cannabinoids and pain: new insights from old molecules. Front Pharmacol. 2018;9:1259.
   PubMed Web of Science ®Google Scholar
• Hindocha C, Lawn W, Freeman TP, et al. Individual and combined effects of cannabis and tobacco on drug reward processing in non-dependent users. Psychopharmacology (Berl). 2017;234:3153–3163.
   PubMed Web of Science ®Google Scholar
• Morgan CJ, Das RK, Joye A, et al. Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav. 2013;38:2433–2436.
   PubMed Web of Science ®Google Scholar
• Melamede R. Cannabis and tobacco smoke are not equally carcinogenic. Harm Reduct J. 2005;2:21.
   PubMedGoogle Scholar
• Hindocha C, Freeman TP, Winstock AR, et al. Vaping cannabis (marijuana) has the potential to reduce tobacco smoking in cannabis users. Addiction. 2016;111:375.
   PubMed Web of Science ®Google Scholar
• Prud’homme M, Cata R, Jutras-Aswad D. Cannabidiol as an intervention for addictive behaviors: a systematic review of the evidence. Subst Abuse. 2015;9:33–38.
   PubMed Web of Science ®Google Scholar
• Morales M, Bonci A. Getting to the core of addiction: hooking CB2 receptor into drug abuse? Nat Med. 2012;18:504–505.
   PubMedGoogle Scholar
• Calpe-Lopez C, Garcia-Pardo MP, Aguilar MA. Cannabidiol treatment might promote resilience to cocaine and methamphetamine use disorders: a review of possible mechanisms. Molecules. 2019;24(14):2583.
   Web of Science ®Google Scholar
• Reiman A. Cannabis as a substitute for alcohol and other drugs. Harm Reduct J. 2009;6:35.
   PubMed Web of Science ®Google Scholar
• Capano A, Weaver R, Burkman E. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. Postgrad Med. 2020;132:56–61.
   PubMed Web of Science ®Google Scholar
• Stewart JC, Rollman BL. Optimizing approaches to addressing depression in cardiac patients: a comment on O’Neil et al. Ann Behav Med. 2014;48:142–144.
   PubMed Web of Science ®Google Scholar
• Celano CM, Daunis DJ, Lokko HN, et al. Anxiety disorders and cardiovascular disease. Curr Psychiatry Rep. 2016;18:101.
   PubMed Web of Science ®Google Scholar
• May HT, Horne BD, Knight S, et al. The association of depression at any time to the risk of death following coronary artery disease diagnosis. Eur Heart J Qual Care Clin Outcomes. 2017;3:296–302.
   PubMed Web of Science ®Google Scholar
• Blessing EM, Steenkamp MM, Manzanares J, et al. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015;12:825–836.
   PubMed Web of Science ®Google Scholar
• Zuardi AW, Shirakawa I, Finkelfarb E, et al. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl). 1982;76:245–250.
   PubMed Web of Science ®Google Scholar
• Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology. 2011;36:1219–1226.
   PubMed Web of Science ®Google Scholar
• Russo EB, Burnett A, Hall B, et al. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005;30:1037–1043.
   PubMed Web of Science ®Google Scholar
• Sales AJ, Fogaca MV, Sartim AG, et al. Cannabidiol induces rapid and sustained antidepressant-like effects through increased BDNF signaling and synaptogenesis in the prefrontal cortex. Mol Neurobiol. 2019;56:1070–1081.
   PubMed Web of Science ®Google Scholar
• Lehrke M, Marx N. Diabetes mellitus and heart failure. Am J Cardiol. 2017;120:S37–S47.
   PubMed Web of Science ®Google Scholar
• Henning RJ. Type-2 diabetes mellitus and cardiovascular disease. Future Cardiol. 2018;14:491–509.
   PubMed Web of Science ®Google Scholar
• Imtiaz S, Rehm J. The relationship between cannabis use and diabetes: results from the national epidemiologic survey on alcohol and related conditions III. Drug Alcohol Rev. 2018;37:897–902.
   PubMed Web of Science ®Google Scholar
• Alshaarawy O, Anthony JC. Cannabis Smoking and Diabetes Mellitus: Results from Meta-analysis with Eight Independent Replication Samples. Epidemiology. 2015;26:597–600.
   PubMed Web of Science ®Google Scholar